search icon
      blog search icon

      Here is why Jaguar Health Inc. (JAGX) stock had a BAD Friday? - Stocks Telegraph

      By Asim Kamal

      Published on

      September 7, 2021

      4:25 AM UTC

      Here is why Jaguar Health Inc. (JAGX) stock had a BAD Friday? - Stocks Telegraph

      Jaguar Health Inc. (JAGX) shares declined 13.79% in after-hours on Friday, September 3, 2021, and closed the weekly trading at $1.00. Even in the regular trading session of Friday, JAGX’s stock lost 3.33%. JAGX shares have risen 236.72% over the last 12 months, and they have moved down 4.92% in the past week. Over the past three months, the stock has lost 37.30%, while over the past six months, it has slid down 46.54%.

      Let’s have a look at its recent news and developments.

      JAGX reverse stock split

      On September 3, 2021, Jaguar Health, Inc announced a reverse stock split of its issued and outstanding voting common stock at an exchange ratio of 1-for-3, effective, Wednesday, September 8, 2021. The Company’s Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date and will remain listed on The Nasdaq Capital Market under the symbol JAGX.

      JAGX AGM of Stockholders

      On September 3, 2021, Jaguar Health, Inc (JAGX) announced the voting results of the Annual Meeting of Stockholders.

      A total of six proposals were presented for approval and out of a total of six, 5 proposals were approved by the shareholders. Proposal number 3 did not get a sufficient vote in favour and it was not approved.

      Proposal number 3 was to approve an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended (the “COI”), to increase the number of authorized shares of Common Stock from 150,000,000 shares to 290,000,000 shares.

      JAGX presentation at the 2021 IDWeek Annual Meeting

      On August 23, 2021, Napo Pharmaceuticals, which is the wholly-owned subsidiary of Jaguar Health, Inc (JAGX) announced that an abstract associated with an exploratory clinical study on the effect of crofelemer (Mytesi®) on the gastrointestinal microbiome in people living with HIV/AIDS (PLWHA) has been submitted for consideration for presentation at IDWeek 2021, which takes place virtually from September 29 to October 3.

      Commercialization of Crofelemer and Lechlemer

      On August 19, 2021, Napo Pharmaceuticals, Inc (Napo), the wholly-owned US subsidiary of Jaguar Health, Inc (JAGX) signed a license agreement with Napo’s Italian subsidiary, Napo EU S.p.A., to study, develop, and commercialize Napo’s plant-based crofelemer and lechlemer drug product candidates in the European Union and specified non-EU countries in Europe for specific indications.

      Completion of Lechlemer (NP-300) study

      On August 17, 2021, Napo Pharmaceuticals, Inc completed an additional preclinical toxicology study intended to support the continued development of NP-300 for the symptomatic relief of diarrhea from cholera and other infectious diarrheal conditions. The study findings support the Investigational New Drug (IND) application Napo plans to file for lechlemer for this indication in the first half of 2022.

      Conclusion

      In our opinion, the reverse stock split news was the reason behind its poor performance on Friday and it can further decline on Tuesday, after the long weekend.

      More From Stocks telegraph